Physicians' Academy for Cardiovascular Education

New left ventricular assist device lowers stroke risk vs. gold standard

3' education - Mar. 9, 2018 - ACC 2018, Orlando, FL, USA - James Januzzi - Boston, MA, USA

There is hope for treatment of HFpEF

3' education - Nov. 24, 2017 - WCN congress, Amsterdam, The Netherlands - Prof. Carolyn Lam, MD - Singapore

Highly adhering to a plant-based diet is associated with a lower risk of developing HF

3' education - Nov. 14, 2017 - AHA 2017 - Anaheim, CA - AHA 2017 - Anaheim, CA, USA

Heart failure & Diabetes: Time for a more unified approach

10' education - Oct. 19, 2017 - Barcelona, Spain - Stefan D. Anker MD, Berlin, Germany - PACE-CME symposium held at ESC 2017

Step forward in telemonitoring through use of an algorithm that risk-stratifies HF patients

3' education - May 31, 2017 - ESC HF 2017, Paris

Disappointing results with therapy for acute heart failure

3' education - Apr. 30, 2017 - ESC HF 2017, Paris

Challenges in Heart Failure management: Diabetes and Renal Impairment

10' education - May 12, 2017 - Paris, France - Martin Cowie, MD - ESC Heart Failure, Paris

SGLT2 inhibition & Heart Failure: Lessons from EMPA REG Outcome

10' education - May 9, 2017 - Paris, France - Per-Henrik Groop, MD - ESC Heart Failure, Paris

New diabetes drugs and heart failure: What have we learnt?

10' education - May 6, 2017 - Paris, France - John McMurray, MD - ESC Heart Failure, Paris

New diabetes treatments with CV benefit: A changing role for the cardiologist

3' education - Apr. 19, 2017 - Robert J Chilton, MD (San Antonio, TX, USA)

HFpEF in older adults: TTR amyloid, under diagnosed and treatable?

3' education - Nov. 12, 2016 - New Orleans, LA, USA - Mathew S. Maurer, MD (New York, NY, USA)
##SCROLLER_ITEMS_FULL_TITLE##

Peak VO2 maintained in HF patients on IV iron therapy

3' education - Nov. 22, 2016 - AHA 2016 - Dirk Jan van Veldhuisen, MD (UMC Groningen, The Netherlands)
##SCROLLER_ITEMS_FULL_TITLE##

Iron deficiency in the new HF guidelines

3' education - Aug. 29, 2016 - Peter van der Meer, MD - University Medical Center Groningen, The Netherlands
##SCROLLER_ITEMS_FULL_TITLE##

Extra work of checking device data weekly does not translate into benefit for HF patient

3' education - Oct. 25, 2016 - ESC - 2016 Rome - Martin Cowie, MD - National Heart & Lung Institute, London, UK
##SCROLLER_ITEMS_FULL_TITLE##

Heart failure news at the ESC

10' education - Aug. 29, 2016 - ESC - 2016 Rome - Frank Ruschitzka, MD - University Heart Center, Zurich, Switzerland
##SCROLLER_ITEMS_FULL_TITLE##

Heart Failure news from ESC 2016 at a glance

3' education - Sep. 21, 2016 - ESC - 2016 Rome - Prof. Mariell Jessup (Philadelphia, PA, USA)

HF & Diabetes: SGLT2 inhibition a paradigm shift?

10' education - Aug. 29, 2016 - ESC 2016, Rome, Italy - John McMurray, MD University of Glasgow United Kingdom - Recorded at PACE-CME symposium held during ESC 2016 in Rome

The future of HF management: How does potassium binding fit within pharmacological treatment of heart failure?

10' education - June 28, 2016 - ESC HF 2016, Florence, Italy - Kenneth Dickstein, MD - University of Bergen Stavanger University Hospital, Norway

Heart failure and SGLT2 inhibition: understanding the mechanism for potential benefit

10' education - May 21, 2016 - ESC HF 2016, Florence, Italië - Naveed Sattar, MD - Glasgow Universtiy, Glasgow, UK

Hyperkalemia: Novel treatment strategies to manage potassium levels in heart failure

10' education - May 23, 2016 - ESC HF 2016, Florence, Italy - Peter van der Meer, MD - UMCG Groningen, The Netherlands

RAAS inhibition in heart failure: Corner stone of therapy & potassium homeostasis

10' education - May 23, 2016 - ESC HF 2016, Florence, Italy - Faiez Zannad, MD - CHU- Nancy University Nancy, France

SGLT2 inhibition and cardiovascular outcomes: lessons from recent clinical trials

10' education - May 21, 2016 - ESC HF 2016, Florence, Italy - David Fitchett, MD - University of Toronto, ONT, Canada

Current treatment of Diabetes in Heart Failure

10' education - May 21, 2016 - ESC HF 2016, Florence, Italy - Adriaan Voors, MD - UMCG Groningen, The Netherlands

Two additions to the therapeutic armory to treat HFrEF

3' education - Apr. 1, 2016 - VBWG Meeting at ACC 2016, Chicago, IL, USA - Scott D. Solomon, MD - Boston, MA, USA

Managing cardiorenal syndrome in the context of heart failure

3' education - Apr. 1, 2016 - VBWG Meeting at ACC 2016, Chicago, IL, USA - Peter A. McCullough, MD - Dallas, TX, USA
##SCROLLER_ITEMS_FULL_TITLE##

New 2016 ESC Heart Failure Guidelines

3' education - May 21, 2016 - ESC HF 2016, Florence, Italy - Adriaan Voors (Groningen, The Netherlands)
##SCROLLER_ITEMS_FULL_TITLE##

The spectrum of Heart Failure

10' education - May 11, 2016 - Boston, MA, USA - Dr. Marc Pfeffer
##SCROLLER_ITEMS_FULL_TITLE##

Review of cardiovascular safety of DPP4 inhibitors

3' education - May 6, 2016 - Dubai, UAE - Dr Sanjay Rajagopalan, MD, Maryland
##SCROLLER_ITEMS_FULL_TITLE##

No benefit of direct renin inhibition in HF in ATMOSPHERE trial

3' education - Apr. 11, 2016 - ACC 2016, Chicago, IL, USA - Lars Køber
##SCROLLER_ITEMS_FULL_TITLE##

HF Summit : innovation in clinical care in heart failure

10' education - Oct. 31, 2015 - Barcelona, Spain - Prof. Adriaan Voors and Prof. Martin Cowie

Nut consumption inversely associated with risk on AF and HF

Literature - July 10, 2018 - Larsson SC, et al. - Heart 2018
A prospective study showed an inversed association between nut consumption and incidence of atrial fibrillation and heart failure in the Swedish population.

A prospective study showed an inversed association between nut consumption and incidence of atrial fibrillation and heart failure in the Swedish population.

Mechanisms involved in HFpEF and how they are or may be targeted for therapy

Literature - June 26, 2018 - Lam CSP et al., - Eur Heart J 2018

This review describes six mechanisms underlying HFpEF with potential translational significance; three haemodynamic mechanisms and cellular/molecular mechanisms.

No increased risk of below-knee amputation with canagliflozin in real-world study

News - June 25, 2018

ADA 2018 In the OBSERVE-4D real world study, canagliflozin did not result in increased risk of below-knee amputation in T2DM patients or patients with established CVD.

Initiation of SGLT2i therapy associated with decreased CV outcomes outside the US and Europe

Literature - June 14, 2018 - Kosiborod M, et al. - J Am Coll Cardiol 2018

In a pooled analysis of databases of 6 different countries, the initiation of SGLT2i was associated with lower risks of CV outcomes, as compared with other glucose-lowering drugs.

Changes in NT-proBNP levels identify T2DM patients at high risk for major CV events

Literature - June 6, 2018 - Jarolim P et al. - Diab Care 2018
In type 2 diabetes patients with a recent acute coronary syndrome, NT-proBNP concentrations and absolute changes therein identified those at high risk for adverse CV outcomes, including heart failure.

In type 2 diabetes patients with a recent acute coronary syndrome, NT-proBNP concentrations and absolute changes therein identified those at high risk for adverse CV outcomes, including heart failure.

SGLT2 inhibition lowers CV risk in type 2 diabetic patients with and without CVD

Literature - June 4, 2018 - Cavender MA, et al. - J Am Coll Cardiol 2018
Type 2 diabetic patients treated with SGLT2i had a lower risk of death and HF when compared with other glucose-lowering drugs, regardless of the presence of CVD.

Type 2 diabetic patients treated with SGLT2i had a lower risk of death and HF when compared with other glucose-lowering drugs, regardless of the presence of CVD.

Higher mortality in HFrEF patients compared to those with HFmrEF or HFpEF

Literature - May 31, 2018 - Lam CSP et al. - Eur Heart J 2018

In a prospective study the risk of all-cause death was comparable in HFpEF and HFmrEF, which was lower than in HFrEF patients. Mortality and HFH were lowest HFpEF patients.

GRAND DEBATE | HFmrEF is similar to HFrEF – or not?

ESC Heart Failure 2018, Vienna
ESC Heart Failure 2018, Vienna

ESC 2018 In this debate, it became clear that not all are convinced yet about the use of the new ejection fraction category HFmrEF that was introduced in the latest ESC HF Guidelines in 2016.

Much progress in HF therapy in past 3 decades, especially with combination therapy

News - May 28, 2018
A network meta-analysis showed that incremental use of disease-modifying therapies lowers hospitalizations and mortality, which supports guideline recommendations.

ESC HF 2018 A network meta-analysis showed that incremental use of disease-modifying therapies lowers hospitalizations and mortality, which supports guideline recommendations.

‘Exergaming’ can help some HF patients to become more active and feel better

News - May 27, 2018
Playing of video games that require rigorous physical exercise yielded significant effects on exercise capacity and well-being in some HF patients.

ESC HF 2018 Playing of video games that require rigorous physical exercise yielded significant effects on exercise capacity and well-being in some HF patients.

Beta-blockers reduce all-cause and CV mortality in non-diabetic and diabetic HF patients

News - May 27, 2018
A large study on individual patient data shows that diabetic HF patients who are not obese have the highest mortality. Obesity attenuates the prognostic impact of beta-blockers.

ESC HF 2018 A large study on individual patient data shows that diabetic HF patients who are not obese have the highest mortality. Obesity attenuates the prognostic impact of beta-blockers.

First truly world-wide AHF registry reveals differences across the globe

News - May 26, 2018
The REPORT-HF registry allows prospective and longitudinal analyses across seven regions in the world. Patients with acute heart failure are not the same everywhere, which affects therapy.

ESC HF 2018 The REPORT-HF registry allows prospective and longitudinal analyses across seven regions in the world. Patients with acute heart failure are not the same everywhere, which affects therapy.